Emerging Strategies for the Prevention of Immune Toxicities Associated with T-cell-Engaging Cancer Therapies.

The introduction of bispecific monoclonal antibodies and chimeric antigen receptor T (CAR-T) cell therapies has shifted the focus for novel treatment strategies from chemotherapy to immunotherapy in hematologic malignancies. Despite the promising efficacy, bispecific antibodies and CAR-T cells are associated with a unique and predictable side-effect profile where T-cell over-activation frequently leads to cytokine release syndrome (CRS) after the first dose, and sometimes recurring after subsequent doses. Here, we discuss emerging strategies to mitigate CRS in this setting.